Roivant Sciences announced that the phase 2 study by its subsidiary Kinevant Sciences showed Namilumab did not provide treatment benefit for chronic active pulmonary sarcoidosis. The study failed to meet primary and secondary endpoints, leading to discontinuation of namilumab development for this condition.